Developing the Next Wave of Innovation in Biopharma
The Biopharma Division at NJII was established to help our partners in the industry overcome challenges they face as they develop the next wave of cell and gene therapies.
We have a multi-million dollar, state-of-the-art Cell and Gene Therapy Development and manufacturing center and related workforce development programs which are brought to market via a wholly owned for-profit subsidiary doing business as BioCentriq.
Our mission is to support industry-wide advancement, so we also run an incubator that is currently funded by the EDA of promising start-ups.
The incubator program is called the BioFoundry and the first cohort, which consisted of five very promising start-ups in cell and gene therapy, concluded in early 2021.
Why Choose Us?
Fast & Cost
See Our Facility
Watch the BioCentriq Video
BioCentriq, our state-of-the-art process development and cGMP manufacturing center features two GMP suites for clinical production of cell & gene therapies and a process development pilot plant.
Our clients come to us for fast and cost effective development services that are secure, confidential and flexible. We do not retain any intellectual property, and work with our clients to customize a development process that is right for them.